Related Experiment Video

Updated: May 12, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Hit parade for adoptive cell transfer therapy: the best T cells for superior clinical responses

Daniel E Speiser1

  • 1Department of Oncology and Ludwig Center for Cancer Research, University of Lausanne, Lausanne, Switzerland. doc@dspeiser.ch

Cancer Discovery
|April 13, 2013
PubMed

Insights

Adoptive cell transfer (ACT) shows promise, but treatment choices are complex. A new technology helps characterize patient T-cell responses, potentially optimizing this therapy.

Area of Science:

  • Immunology
  • Cellular Therapy
  • Biomedical Research

Background:

  • Adoptive cell transfer (ACT) is a promising immunotherapy with significant clinical potential.
  • The complexity and numerous variables in ACT present challenges for treatment selection and optimization.

Purpose of the Study:

  • To introduce and evaluate a novel technology for characterizing patient T-cell responses in the context of ACT.
  • To explore the potential of this technology in identifying biomedical correlates of protection for ACT.

Main Methods:

  • Utilized a novel technological platform for detailed characterization of T-cell responses.
  • Applied the technology to patient samples undergoing ACT.

Main Results:

  • The novel technology provides a comprehensive profile of T-cell responses.
  • The study demonstrates the feasibility of using this approach for patient stratification and treatment monitoring.

Conclusions:

  • Systematic application of this T-cell characterization technology can aid in understanding ACT variability.
  • This approach may lead to the identification of biomarkers for predicting treatment success and optimizing ACT strategies.

More Related Videos

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy06:51

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System10:24

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System

Published on: October 5, 2015

Related Concept Videos

Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.